Other studies have described variable findings on the influence of CFTR mutations in early pancreatic cancer, including a recent analysis in which investigators found no significant difference in the rate of EPOC among patients with the most common CFTR variants (ΔF508 mutation and 5T allele) as compared to a control group [69]. The gene discussed is CFTR; the disease is familial pancreatic carcinoma.